This forum is for questions about medical issues and research aspects of
Hepatitis C such as, questions about being newly diagnosed, questions about current treatments, information and participation in discussions about research studies and clinical trials related to Hepatitis. If you would like to communicate with other people who have been touched by Hepatitis, please visit our new
Hepatitis Social/Living with Hepatitis forum
http://www.nature.com/ncpgasthep/journal/v4/n1s/full/ncpgasthep0691.html
Believe me, if they came out with something I would have gotten ahold of you asap. Whether you were posting or not I would have emailed you if I heard of anything that would have made it a better treatment for you with your Thalessemia.
I promise.
Bob
How are you feeling? I'm so glad your SVR, and I know you are!
Bob
Bob
Beagle Bailey
Bob
See aranesp.com
I've read a few people who have used it (SFBay, I think). No sx's that I've noticed - but I did not use procrit the first time around. Hemo administers, not an rx for me. Result of increased riba 800 to 1200. Expensive stuff, about $2k a pop.
Thanks
Bob
It’s good to hear from you again. I checked with clinicaltrials.gov and there is a Taribavirin trial recruiting in the Los Angeles area:
http://clinicaltrials.gov/ct/show/NCT00446134?order=1
Unfortunately, a history of thalassemia or other hemoglobinopathies (even if the hemoglobin is normal) is noted in the exclusion criteria. It still sounds as if PI’s are your best bet for now. Have you talked with your doctor about a course of PEG-IFN monotherepy? I think this would probably be accepted as SOC in terms of insurance coverage, but it might be to no avail given your previous relapse. Even still, possibly something to consider and discuss with your doctor.
Talk care,
Bill
Bob
As a GT-2 relapser however, I’d ask Schiff or his staff about the numbers (if any available) regarding IFN monotherepy response rates. He would be the man in the know.
Take care,
Bill
Here's the abstract from their presentation at EASL in April:
"Results: The mean baseline HCVRNA level was 6.41ogl0, and 66% of
patients were infected with HCV genotype I . PK parameters for HCV-
796 administered with PEG were generally similar to those observed with
HCV-796 monotherapy. At all doses tested, HCV-796 when combined with
PEG reduced plasma HCVRNA levels to a greater extent than PEG alone.
At day 14, the mean reduction in HCVRNA ranged from 3.3-3.5 loglo in
the combination groups vs. 1.6 loglo in the PEG group. Activity differed
by HCV genotype. Mean reductions at day 14 for genotype I ranged
from 2.6-3.21og10 in the combination groups vs. l.2loglo for PEG. For
genotype non-1 the respective reductions were 3.5-4.8 loglo vs. 2.6 loglo.
At HCV-796 doses of 250mg q12h or higher, combination with PEG
resulted in 33-67% of genotype 1 patients with reductions from baseline
>3logl0 on day 14 (13-17% below 50 IUlmL). For genotype non-I, 67-
100% had reductions >31oglo on day 14 (50-75% below 50 IUlmL).
Common adverse events in all groups were those typically associated with
interferons, including headache, chills, rash and myalgia. There were no
dose-limiting toxicities observed through the highest dose of HCV-796
tested.
Conclusions: The combination of HCV-796 and PEG provides antiviral
activity across multiple HCV genotypes that is greater than either agent
used alone. Clinical studies of more long-term administration are needed
to determine if these effects are durable."
http://www.clinicaltrials.gov/ct/show/NCT00367887?order=11
Think this means UM and Shands in Gainesville
I'm sure that there are others who may have had a different repoire w/Shands. So, I wouldn't rule them out.
Susan